Anosmia in Neurodegenerative disorders

摘要: Since the discovery of olfactory dysfunction in Parkinson’s disease (PD) and Alzheimer’s disease (AD) just over three decades ago, research into PD AD has grown vastly. It appeared that is similar AD. However, recent studies show severity differs between AD. Olfactory appears to be stable during progression severity except for odour discrimination. In AD however, identification, discrimination threshold associated with degree dementia. has been found both an are preceded at approximately five years by olfactory dysfunction before presence typical symptoms. Typical symptoms are bradykinesia, rest tremor rigidity. For cognitive impairment and memory deficits. Also, can identify future or developers from an risk group. However, predictive value a general population unknown. Another difference treatment response. Olfactory improves in AD acetylcholinesterase inhibitors (ChEI), where PD, olfaction unaffected by typical dopaminergic treatment. There number explanations this difference, among which underlying mechanism more complex comprises multiple system, e.g. system (AChE) activity. has recently been suggested AChE important than the system. Olfactory testing very useful early detection differential diagnosis and could clinical settings, but further needed investigate the underlying mechanisms possibilities inclusion research could focus on link movement as seen animals. Another possible line emotion lack thereof